Marketing Applications, Product Launches, Commencement of Studies, Collaborations, and Release of Funding - Research Report on Biogen Idec, Illumina, Santarus, Celsion, and BioCryst

NEW YORK, July 24, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Illumina, Inc. (NASDAQ: ILMN), Santarus, Inc. (NASDAQ: SNTS), Celsion Corporation (NASDAQ: CLSN), and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Biogen Idec Inc. Research Report

On July 19, 2013, Biogen Idec Inc. (Biogen Idec) announced that the US Food and Drug Administration and the European Medicines Agency have accepted the marketing applications for the review of PLEGRIDY (peginterferon beta-1a), the Company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (MS). According to the Company, the regulatory applications included positive one-year results from the two-year global Phase 3 ADVANCE study. In that study, data demonstrated PLEGRIDY met all primary and secondary endpoints by significantly reducing disease activity including relapses, disability progression and brain lesions compared to placebo, and showed favorable safety and tolerability profiles at one year. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/BIIB]

Illumina, Inc. Research Report

On July 18, 2013, Illumina Inc. (Illumina) announced the availability of its Phasing Analysis Service created by the Company's FastTrack Services lab through the Illumina Genome Network (IGN). According to Illumina, the new sample-to-answer service delivers human whole-genome phase information, thus empowering gene mapping studies with a more comprehensive view of genomic variation. The Company further said that with Phase data, researchers can better understand the effect of genotype on phenotype and variant interaction within a gene. Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions business, said, "Customers who participated in the beta testing used the service for a diverse range of applications, from human population studies to the identification of variants causing rare disease. Early customer feedback has been overwhelmingly positive." According to the Company, the new Phasing Analysis Service is available for immediate ordering and as an add-on to the IGN Whole-Genome Analysis Service, which delivers results within twelve weeks.The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/ILMN]

Santarus, Inc. Research Report

On July 18, 2013, Santarus, Inc. (Santarus) announced the completion of enrollment in the CONTRIBUTE clinical study, which is designed to evaluate the incremental benefit of adding UCERIS (budesonide) extended release 9mg tablets to oral aminosalicylate (5-ASA) therapy for the induction of clinical remission in adult patients with active, mild to moderate ulcerative colitis. According to the Company UCERIS is currently approved in the US for the induction of remission in patients with active, mild to moderate ulcerative colitis. 509 patients were enrolled in the CONTRIBUTE study, a multicenter, randomized, double-blind placebo controlled clinical trial. According to Santarus, the primary endpoint of the study is clinical remission, which is defined as a score of 0 for both rectal bleeding and stool frequency on the Ulcerative Colitis Disease Activity Index (UCDAI) scale. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/SNTS]

Celsion Corporation Research Report

On July 19, 2013, Celsion Corporation (Celsion) and Zhejiang Hisun Pharmaceutical Company Ltd. (Hisun) announced that they have entered into a Memorandum of Understanding to pursue ongoing collaborations for the continued clinical development of ThermoDox as well as the technology transfer relating to the commercial manufacture of ThermoDox for the greater China territory. According to the Company, the key provisions of the collaboration include: Hisun will provide Celsion with non-dilutive financing and the investment necessary to complete the technology transfer of its proprietary manufacturing process and the production of registration batches for China, Hisun will collaborate with Celsion around the clinical and regulatory approval activities for ThermoDox as well as other liposomal formulations with the China state Food and Drug Administration, and Hisun will be granted a right first offer for a commercial license to ThermoDox for the sale and distribution of ThermoDox in the greater China territory. Michael H. Tardugno, Celsion's President and CEO, said, "We are pleased to announce our expanded collaboration with Celsion for the continued development of ThermoDox to treat HCC to patients in China, the world's largest market. China is one of the countries with the highest HCC incidence and mortality and, up until now, there has not been any standard of care for treating intermediate HCC in China." The Full Research Report on Celsion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/CLSN]

BioCryst Pharmaceuticals, Inc. Research Report

On July 11, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced that the Biomedical Advanced Research and Development Authority (BARDA/HHS) has released funding under the current $234.8 million contract to enable completion of a New Drug Application (NDA) filing for intravenous peramivir. According to BioCryst, peramivir is a potent, intravenously administered investigational anti-viral agent that quickly delivers high plasma concentrations to the site of infection. The Company further stated that it has reached an agreement with US Food and Drug Administration in relation to all the requirements for a complete NDA submission. BioCryst expects to submit the peramivir NDA by the end of 2013. The Full Research Report on BioCryst Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-22/BCRX]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports